No Data
No Data
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength
Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025
Express News | Monte Rosa Therapeutics: Year-End Cash & Equivalents Expected to Be $377 Mln as of Dec 31, 2024 and Anticipated to Fund Ops Into 2028
Express News | Monte Rosa Therapeutics: Mrt-8102, a Nek7-Directed Mgd Targeting Diseases Driven by Il-1Β & Nlrp3 Inflammasome, on Track for Ind Filing in H1 2025
Express News | Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Unlock the Full List